I sought an update re' the extended timeframes and the following reply was received from company on 20 Aug.
"We are still on track with a licensing deal for Progenza in Japan. We continue to talk with a number of interested parties. We continue to move the process along as quickly as we have the ability to. Please be assured that every time a request for information comes to us, we respond very quickly. We are talking with very large Japanese organisations and their internal processes can take a longer time than we would anticipate, compared to Regeneus who as a small company can move very quickly on these deals."
RGS Price at posting:
20.0¢ Sentiment: Hold Disclosure: Held
